Immunosuppressants reduce the COVID-19 severity rate by increasing CD96 levels in the plasma
Objective To determine whether immunosuppressants can reduce the severity of COVID-19.Methods Genome-wide association studies(GWAS)data including 19 immuno-suppressants was employed as exposures,and GWAS data of COVID-19 events as outcomes,and a two-sample Mendelian randomization(MR)analysis was conducted.A two-step MR ap-proach was then used to identify potential mediators for the immunosuppressants in reducing the severity of COVID-19.Results The use of immunosuppressants showed no causal association with hospitalization rates among COVID-19 patients(P=0.405;OR=0.974,95%CI:0.916～1.036),but there was a negative causal relationship with severity rates(P=1.09×10-7;OR=0.845,95%CI:0.795～0.899).Mediator MR analysis showed that CD96 acted as a mediator by which immunosuppressants reduce the severity of COVID-19,with a mediating effect of 9.938%.Conclusion Immunosuppressants can lower the severity of COVID-19 and identify a potential mechanism of action,providing a new direction for exploring treatment op-tions.It also offers health guidance for patients with COVID-19 combined with immune disor-ders.
NETL
NSTL
万方数据
